Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
Signal Transduction in the Blood-Brain Barriers
Differential roles of microglia and monocytes in the inflamed central nervous system.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
Study hints of rituximab MS benefit
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
The role of T cell apoptosis in nervous system autoimmunity.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Good Early Results for HERV Suppressor in MS
Small internal jugular veins with restricted outflow are associated with severe multiple sclerosis: a sonographer-blinded, case--control ultrasound study.
Immunology 2014
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Ofatumumab
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Pages